Payment overview · 2025
General Payments
$487.92
26 reported records · 9 companies
Healthcare provider profile · identity verified
Neelkant Raya, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LANCASTER, OH · NPI 1760468953
Verified facts
What the public records show
CMS Open Payments records show Neelkant Raya, MD received $487.92 in general payments during 2025 across 26 reported records.
PFIZER INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.58 | 21.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.78 | 20.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.68 | 17.8% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.09 | 11.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.26 | 8.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.36 | 7.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.50 | 6.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.93 | 4.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.74 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.92 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $97.78 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $88.25 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.25 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.68 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.09 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 753 | 214 |
| Metoprolol Succinate | Metoprolol Succinate | 577 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 526 | 149 |
| Omeprazole | Omeprazole | 485 | 145 |
| Losartan Potassium | Losartan Potassium | 484 | 124 |
| Lisinopril | Lisinopril | 446 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 112 |
| Furosemide | Furosemide | 322 | 92 |
| Gabapentin | Gabapentin | 271 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 73 |
| Potassium Chloride | Potassium Chloride | 250 | 78 |
| Carvedilol | Carvedilol | 244 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 213 | 59 |
| Metformin Hcl | Metformin Hcl | 206 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 55 |
| Metformin Hcl Er | Metformin Hcl | 198 | 60 |
| Montelukast Sodium | Montelukast Sodium | 198 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 47 |
| Eliquis | Apixaban | 169 | 48 |
| Doxazosin Mesylate | Doxazosin Mesylate | 167 | 48 |
| Alprazolam | Alprazolam | 166 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 51 |
| Trazodone Hcl | Trazodone Hcl | 147 | 45 |
| Donepezil Hcl | Donepezil Hcl | 140 | 36 |
| Spironolactone | Spironolactone | 140 | 42 |
| Memantine Hcl | Memantine Hcl | 136 | 32 |
| Alendronate Sodium | Alendronate Sodium | 133 | 46 |
| Sertraline Hcl | Sertraline Hcl | 132 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 123 | 32 |
| Finasteride | Finasteride | 120 | 35 |
| Simvastatin | Simvastatin | 118 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 31 |
| Allopurinol | Allopurinol | 110 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 35 |
| Tramadol Hcl | Tramadol Hcl | 98 | 31 |
| Cephalexin | Cephalexin | 92 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 25 |
| Prednisone | Prednisone | 88 | 64 |
| Glimepiride | Glimepiride | 87 | 31 |
| Warfarin Sodium | Warfarin Sodium | 82 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 29 |
| Valsartan | Valsartan | 78 | 20 |
| Famotidine | Famotidine | 76 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 71 | 56 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 21 |
| Buspirone Hcl | Buspirone Hcl | 59 | 17 |
| Synthroid | Levothyroxine Sodium | 57 | 19 |
| Ozempic | Semaglutide | 56 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Glipizide | Glipizide | 52 | 13 |
| Levofloxacin | Levofloxacin | 52 | 46 |
| Azelastine Hcl | Azelastine Hcl | 51 | 21 |
| Celecoxib | Celecoxib | 51 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Meclizine Hcl | Meclizine Hcl | 48 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Meloxicam | Meloxicam | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Nifedipine Er | Nifedipine | 39 | 15 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 33 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 11 |
| Acyclovir | Acyclovir | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 13 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Jardiance | Empagliflozin | 27 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Azithromycin | Azithromycin | 23 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.92 · 26 records | PFIZER INC. | AIRSUPRA, AREXVY, CREON, Cologuard Collection Kit, ELIQUIS, Kerendia, Korlym, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, SHINGRIX, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error